Alnylam Stock Crashes Nearly 30% as Company Lowers Full-Year Revenue Outlook
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
/ 58 items
#XY Earnings Movers↓
Teladoc Cuts 2026 Outlook as BetterHelp Cash-Pay Demand Weakens
Teladoc reported Q2 revenue of $606.9M (down 4%), missing estimates. BetterHelp struggles led to a full-year guidance cut.
GE HealthCare Beats Q2 Estimates on Record Orders, Weighs Sale of Struggling Patient Care Unit
GE HealthCare posts record 11.1% order growth and $5.3B revenue in Q2 2026, beating estimates. Stock jumps as it reviews Patient Care unit sale.
Biogen Beats Q2 Estimates as Newer Drugs Drive Growth
Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%.
Mixed Q2 for Humana: Earnings Beat and Cost Control, but No Guidance Raise Sparks Selloff
Humana posts $7.61 adjusted EPS, topping estimates as costs remain in line; shares decline after full-year guidance is reaffirmed without an increase.
Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.